|
1) Gheorghiade M, Abraham WT, Albert NM, et al. Relationship between admission serum sodium concentration and clinical outcome in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry. Eur Heart J. 2007; 28: 980-8
|
|
|
|
2) Szatalowicz VL, Arnold PE, Chaimovitz C, et al. Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. N Engl J Med. 1981; 305: 263-6
|
|
|
|
|
|
3) Alehagen U, Dahlstrom U, Rehfeld JF, et al. Association of copeptin and N-terminal proBNP concentrations with risk of cardiovascular death in older patients with symptoms of heart failure. JAMA. 2011; 305: 2088-95
|
|
|
|
|
|
4) Fukuyama H, Nakamura T, Saito T, et al. Urinary excretion of aquaporin-2 water channel exaggerated dependent upon vasopressin in congestive heart failure. Kidney Int. 2004; 66: 1387-92
|
|
|
|
|
|
5) Konstam MA, Gheorghiade M, Burnett JC Jr, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome Trial. JAMA. 2007; 297: 1319-31
|
|
|
|
|
|
6) Gheorghiade M, Gattis WA, OʼConnor, CM, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure. A Randomized Controlled Trial. JAMA. 2004; 291: 1963-71
|
|
|
|
|
|
7) Hori M. Tolvaptan for heart failure patients with volume overload. Cardiovasc Drug Ther. 2011 May 3. [Epub ahead of print]
|
|
|
|
|
|
8) Costello-Boerrigter LC, Boerrigter G, Cataliotti A, et al. Renal and anti-aldosterone actions of vasopressin-1 receptor antagonism and B-type natriuretic peptide in experimental heart failure. Circ Heart Fail. 2010; 3: 412-9
|
|
|
|
|
|
9) Mondritzki T, Kolkhof P, Sabbah HN, et al. Differentiation of arginine vasopressin antag-onistic effects by selective V2 versus dual V2/V1a receptor blockade in a preclinical heart failure model. Am J Ther. 2011; 18: 31-7
|
|
|
|
|
|
10) Abraham WT, Shamshirsaz AA, McFann K, et al. Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients. J Am Coll Cardiol. 2006; 47: 1615-21
|
|
|
|
|
|
11) Aronson D, Verbalis JG, Mueller M, et al. Short- and long-term treatment of dilutional hyponatraemia with satavaptan, a selective arginine vasopressin V2 -receptorantagonist: the DILIPO study. Eur J Heart Fail. 2011; 13: 327-36
|
|
|
|
|
|
12) Gheorghiade M, Abraham WT, Albert NM, et al. Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry. Eur Heart J. 2007; 28: 980-8
|
|
|
|
|
|
13) Gheorghiade M, Rossi JS, Cotts W, et al. Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE Trial. Arch Intern Med. 2007; 167: 1998-2005
|
|
|
|
|
|
14) Abraham WT, Aranda JM, Boehmer JP, et al. Rationale and Design of the Treatment of Hyponatremia Based on Lixivaptan in NYHA Class III/IV Cardiac Patient Evaluation (THE BALANCE) Study. Clin Trans Sci. 2010; 3: 249-53
|
|
|
|
|